Safety and Pharmacokinetics of Oral Islatravir (MK-8591) Once Monthly in Participants at Low Risk of Human Immunodeficiency Virus 1 (HIV-1) Infection (MK-8591-016)

NCT04003103 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

242

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV-1 Infection

Interventions

DRUG: Islatravir
DRUG: Placebo

Sponsor

Merck Sharp & Dohme LLC